Physician profile
Ritu Saha
NPI 1639439748
$6,389.83
in general payments reported to CMS, 2019-2025
34 companies · $2,223 in 2025
The $2,223 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $659 · 2020: $47.58 · 2021: $64.47 · 2022: $759 · 2023: $1,253 · 2024: $1,383 · 2025: $2,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,828 · Education: $31.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,827.73 |
| Education | $31.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,730.83 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $894.80 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $784.62 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $459.07 | 2019-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $386.30 | 2023-2025 | |
| Ardelyx, INC. | $202.31 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $202.01 | 2019-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $171.98 | 2022-2025 | Dupixent |
| Pfizer INC. | $156.97 | 2020-2025 | |
| Intercept Pharmaceuticals, INC. | $140.34 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $118.58 | 2019-2024 | Dificid |
| Madrigal Pharmaceuticals | $113.51 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $103.21 | 2022-2024 | Rebyota, Clenpiq |
| Celgene Corporation | $95.63 | 2022-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $89.68 | 2024-2025 | Iqirvo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $87.91 | 2022-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $85.43 | 2024-2025 | Voquezna |
| Lucid Diagnostics INC. | $76.55 | 2024 | |
| Alnylam Pharmaceuticals INC. | $67.42 | 2023-2025 | Givlaari |
| Daiichi Sankyo INC. | $52.75 | 2021-2023 | Injectafer |
| Lilly USA, LLC | $52.26 | 2025 | Omvoh |
| Gilead Sciences, INC. | $46.21 | 2024-2025 | |
| Celltrion USA INC. | $37.74 | 2024-2025 | Zymfentra, Vegzelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.70 | 2023-2024 | Cyltezo |
| Shire North American Group INC | $33.01 | 2019 | |
| Medtronic, INC. | $31.06 | 2025 | Gi Genius |
| Nestle Healthcare Nutrition INC. | $30.59 | 2022-2023 | |
| Boston Scientific Corporation | $27.07 | 2025 | Apollo Esg Nxt System |
| Otsuka America Pharmaceutical, INC. | $17.35 | 2025 | Rexulti |
| Aimmune Therapeutics, INC. | $13.81 | 2025 | Zenpep |
| Amgen INC. | $13.40 | 2022 | |
| Janssen Scientific Affairs, LLC | $11.28 | 2025 | Tremfya |
| Ucb, INC. | $10.97 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritu Saha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.